ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 19 of 49
JMBS 2019, 4(4): 124–129
Clinical Medicine

Activity of the System of Oxidative Stress as Antioxidant Protection in Hypertension with Different Classes of Obesity

Psareva V. G.

Oxidative stress is traditionally regarded as a key factor in the pathogenesis of numerous conditions, including cardiovascular and neurodegenerative diseases, cancer, diabetes and obesity. Oxidative stress is defined as an imbalance between the generation of active forms of oxygen and detoxification with an antioxidant system with a predominance of the first one. Analysis of literary data showed that the problem of studying the activity of oxidative stress in the comorbidity of the most common non-communicable diseases requires clarification and further research. The purpose of the study was to assess the features of the system of oxidative stress as an antioxidant protection in patients with hypertension and various classes of obesity. Materials and methods. We examined 200 patients with arterial hypertension and obesity of the I-II classes who gave informed written consent to participate in the study and met the inclusion criteria. Patients of the main group were divided into subgroups according to the classes of obesity: the first subgroup included 80 patients with obesity of the I class, and the second subgroup comprised 120 patients with obesity of the II class. The control group consisted of 30 practically healthy individuals, matched by age and sex with the patients of the main group. The concentrations of aldosterone and renin in serum were determined. At the renin levels <0.65 ng/ml/h, low-renin hypertension was established, and the renin levels ≥ 0.65 ng/ml/h, high-renin hypertension was noted. Results and discussion. Comparative assessment of indicators in class I and II obesity showed that even within the same degree of hypertension systolic and pulsed blood pressure in class II obesity, were significantly higher than in class I obesity. As compared to class I obesity, in class II obesity, the imbalance of the system of oxidative stress as an antioxidant protection was more pronounced, which showed a significant higher levels of malondialdehyde and diene conjugates, and lower levels of total antioxidant protection. A more pronounced imbalance of the system of oxidative stress as an antioxidant protection in the progression of obesity can be explained by the peculiarities of the pathogenesis of the disease. Obesity is associated with a regulatory disorder in the metabolic balance, which includes lipid metabolism, inflammatory or hormonal processes, in addition to insulin resistance. The pathogenesis of obesity is complex and involves metabolic and hormonal disregulation, chronic inflammation and stress of the endoplasmic reticulum, among other processes that are closely interrelated. Conclusions. In patients with comorbidity of hypertension and obesity, an increase in the class of obesity is associated with a more pronounced imbalance of the system of oxidative stress – antioxidant protection, which was characterized by significantly higher levels of malondialdehyde and diene conjugates and low levels of total antioxidant protection in obesity II degree (as compared to class I obesity).

Keywords: arterial hypertension, obesity, oxidative stress, antioxidant protection

Full text: PDF (Ukr) 212K

  1. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Investig. 2003; 112: 1821–30.
  2. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González A, Esquivel-Chirino C, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci. 2011; 12(5): 3117–32.
  3. Curti MLR, Borges P, Rogero MC, Ferreira SR. Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: Implications for a nutrigenetic approach. J Obes. 2011; 2011: 1–30.
  4. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007; 132(6): 2169–80.
  5. Amirkhizi F, Siassi F, Minaie S, Djalali M, Rahimi A, Chamari M. Is obesity associated with increased plasma lipid peroxidación and oxidative stress in women. ARYA Atheroscler J. 2007; 2: 189–92.
  6. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Investig. 2004; 114(12): 1752–61.
  7. Rzheshevsky AV. Fatal “Triad”: Lipotoxicity, oxidative stress, and phenoptosis. Biochemistry. 2013; 78: 991–1000.
  8. Goossens G.H. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav. 2008; 94(2): 206–18.
  9. Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circulation. 2006; 70(11): 1437–42.
  10. Pihl E, Zilmer K, Kullisaar T, Kairane C, Magi A, Zilmer M. Atherogenic inflammatory and oxidative stress markers in relation to overweight values in male former athletes. Int J Obes. 2006; 30(1): 141–6.
  11. Chrysohoou C, Panagiotakos DB, Pitsavos C, Skoumas I, Papademetriou L, Economou M, et al. The implication of obesity on total antioxidant capacity apparently healthy men and women: The ATTICA study. Nutr Metab Cardiovasc Dis. 2007; 17(8): 590–7.
  12. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome—A new worldwide definition. Lancet. 2005; 366(9491): 1059–62.
  13. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: A regulator of inflammation. J Clin Endocrinol Metab. 2005; 19: 547–66.
  14. Hopps E, Noto D, Caimi G, Averna MR. A novel comoponent of the metabolic syndrome: The oxidative stress. Nutr Metab Cardiovasc Dis. 2010; 20(1): 72–7.
  15. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: A unifying hyopothesis. J Nutr Biochem. 2008; 19(8): 491–504.
  16. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations: Findings from the Third National Health and Nutrition Examination Survey. Diabetes. 2003; 52(9): 2346–52.
  17. Paneni F, Costantino S, Cosentino F. Insulin resistance, diabetes, and cardiovascular risk. Curr Atheroscler Rep. 2014; 16(7): 419.
  18. Yang RL, Shi YH, Hao G. Increasing oxidative stress with progressive hyperlipidemia in human: Relation between malondialdehyde and atherogenic index. J Clin Biochem Nutr. 2008; 43(3): 154–8.
  19. Krzystek-Korpacka M, Patryn E, Hotowy K, Czapinska E, Majda J, Kustrzeba-Wojcicka I, et al. Paraoxonase (PON)-1 activity in overweight and obese children and adolescents: Association with obesity-related inflammation and oxidative stress. Adv Clin Exp Med. 2013; 22: 229–36.
  20. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, LIoyd-Jones D, et al. Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment: A position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens. 2013; 15(1): 14–33.
  21. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010; 72: 219–46.
  22. Sengenes C, Miranville A, Lolmede K, Curat CA, Bouloumie A. The role of endothelial cells in inflamed adipose tissue. J Intern Med. 2007; 262: 415–21.
  23. Marseglia L, D’Angelo G, Manti S, Arrigo T, Barberi I, Reiter RJ, et al. Oxidative stress-mediated aging during the fetal and perinatal periods. Oxid Med Cell Longev. 2014; 2014: 358375.
  24. Sikaris K. The clinical biochemistry of obesity. Clin Biochem Rev. 2004; 25(3): 165–81.
  25. Cristancho AG, Lazar MA. Forming functional fat: A growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol. 2011; 12(11): 722–34.
  26. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, Lima FB. Adipose tissue as an endocrine organ: From theory to practice. J Pediatr. 2007; 83(5 Suppl): 192–203.
  27. Khan N, Naz L, Yasmeen G. Obesity: An independent risk factor systemic oxidative stress. Pak J Pharm Sci. 2006; 19(1): 62–9.
  28. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann NY Acad Sci. 2010; 1212: E1–E19.
  29. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010; 314(1): 1–16.
  30. Neels JG, Olefsky JM. Inflamed fat: What starts the fire? J Clin Investig. 2006; 116: 33–5.
  31. Huffman DM, Barzilai N. Role of visceral adipose tissue in aging. Biochim Biophys Acta. 2009; 1790(10): 1117–23.